American Journal of Ophthalmology
Volume 150, Issue 3 , Pages 315-324.e1, September 2010

Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2

  • Prema Abraham

      Affiliations

    • Black Hills Regional Eye Institute, Rapid City, South Dakota
    • Corresponding Author InformationInquiries to Prema Abraham, Black Hills Regional Eye Institute, 2800 Third Street, Rapid City, SD 57701
    • ,
  • Huibin Yue

      Affiliations

    • Genentech, Inc, South San Francisco, California
    • ,
  • Laura Wilson

      Affiliations

    • Genentech, Inc, South San Francisco, California

Accepted 18 April 2010. published online 02 July 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0002-9394(10)00267-9

doi:10.1016/j.ajo.2010.04.011

American Journal of Ophthalmology
Volume 150, Issue 3 , Pages 315-324.e1, September 2010

Article Tools

* Image Usage & Resolution